Alumis Inc

This study tested a new daily pill, ESK-001, in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces skin severity and is safe, comparing it to a placebo and an existing drug (apremilast). Participants took the pill for 24 weeks and had regular c…

This study tested a new daily pill, ESK-001, in 912 adults with moderate to severe plaque psoriasis. Participants took the drug, a placebo, or an approved psoriasis medicine for 24 weeks. The goal was to see if ESK-001 safely reduces psoriasis severity and improves quality of lif…

This study looked at how the drug ESK001 is processed in people with different levels of liver function. Researchers gave a single dose to 32 volunteers, including healthy people and those with mild, moderate, or severe liver impairment. The goal was to measure drug levels in the…

This study looked at how different levels of kidney function affect the way the body processes a single dose of the drug ESK-001. Sixteen adults with healthy kidneys or mild, moderate, or severe kidney problems took part. Researchers measured drug levels in the blood and checked …

This study checked how a new drug called ESK-001 affects the heart's electrical activity in 52 healthy adults aged 18 to 55. Participants received ESK-001, a placebo (fake drug), and moxifloxacin (a known heart-effect drug) in a random order. The goal was to see if ESK-001 causes…

This early-stage study tested a new drug, A-005, in 135 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and some had a spinal tap to measure drug levels in the brain fluid. The study does not aim to treat any …